Biopharma veteran Geert Cauwenbergh, president and CEO of Rxi Pharmaceuticals Corp., has maintained steadfast faith in the potential of RNAi therapeutics even when the market has not. The Marlborough, Mass.-based RNAi company that he helms has struggled of late, forced in January to execute a 1-for-10 reverse stock split to regain compliance with Nasdaq's minimum bid price rule and to prioritize its pipeline by seeking to out-license dermatology and ophthalmology assets while focusing on immuno-oncology (I-O).